The association of circulating adiponectin levels with pancreatic cancer risk: A study within the prospective EPIC cohort
(2012) In International Journal of Cancer 130(10). p.2428-2437- Abstract
- Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e., decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a casecontrol study nested within European Prospective Investigation into Cancer and Nutrition. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays.... (More)
- Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e., decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a casecontrol study nested within European Prospective Investigation into Cancer and Nutrition. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.230.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.673.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2587399
- author
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- adiponectin, pancreatic cancer, EPIC, cohort study
- in
- International Journal of Cancer
- volume
- 130
- issue
- 10
- pages
- 2428 - 2437
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000301579800022
- scopus:84859104666
- pmid:21681743
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.26244
- language
- English
- LU publication?
- yes
- id
- 4382f9cf-43de-4e7b-b564-25e29382efb8 (old id 2587399)
- date added to LUP
- 2016-04-01 11:01:32
- date last changed
- 2022-02-14 16:16:43
@article{4382f9cf-43de-4e7b-b564-25e29382efb8,
abstract = {{Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e., decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a casecontrol study nested within European Prospective Investigation into Cancer and Nutrition. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.230.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.673.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development.}},
author = {{Grote, Verena A. and Rohrmann, Sabine and Dossus, Laure and Nieters, Alexandra and Halkjaer, Jytte and Tjonneland, Anne and Overvad, Kim and Stegger, Jakob and Chabbert-Buffet, Nathalie and Boutron-Ruault, Marie-Christine and Clavel-Chapelon, Francoise and Teucher, Birgit and Becker, Susen and Montonen, Jukka and Boeing, Heiner and Trichopoulou, Antonia and Lagiou, Pagona and Trichopoulos, Dimitrios and Palli, Domenico and Sieri, Sabina and Tumino, Rosario and Vineis, Paolo and Mattiello, Amalia and Argueelles, Marcial and Duell, Eric J. and Molina-Montes, Esther and Larranaga, Nerea and Chirlaque, Maria-Dolores and Gurrea, Aurelio Barricarte and Jeurnink, Suzanne M. and Peeters, Petra H. M. and Ye, Weimin and Sund, Malin and Lindkvist, Bjoern and Johansen, Dorthe and Khaw, Kay-Tee and Wareham, Nick and Crowe, Francesca L. and Romieu, Isabelle and Rinaldi, Sabina and Jenab, Mazda and Romaguera, Dora and Michaud, Dominique S. and Riboli, Elio and Bueno-de-Mesquita, H. Bas and Kaaks, Rudolf}},
issn = {{0020-7136}},
keywords = {{adiponectin; pancreatic cancer; EPIC; cohort study}},
language = {{eng}},
number = {{10}},
pages = {{2428--2437}},
publisher = {{John Wiley & Sons Inc.}},
series = {{International Journal of Cancer}},
title = {{The association of circulating adiponectin levels with pancreatic cancer risk: A study within the prospective EPIC cohort}},
url = {{http://dx.doi.org/10.1002/ijc.26244}},
doi = {{10.1002/ijc.26244}},
volume = {{130}},
year = {{2012}},
}